Phase II study of cyclophosphamide, vincristine and D.T.I.C. +/- B.C.G. in the treatment of malignant melanoma.
Fifty-three patients with advanced metastatic malignant melanoma were treated with DTIC, vincristine and cyclophosphamide in a 28 day cycle. In addition, 39 were vaccinated with BCG. The BCG treated group showed no significant advantage in response or survival over those treated with chemotherapy alone. Response rate in nodes draining vaccinated areas was not greater than that in equivalent nodes in non-BCG treated patients. Of 50 patients evaluable for response, two showed CR, 15 PR for an overall response rate of 34% (median duration 20 weeks, range 4-77 + weeks). Metastatic sites did not influence response rate. Median survival of all treated patients was 26 weeks, responders 42 weeks, non-responders 18 weeks, p less than 0.025. This regimen may be superior to DTIC alone.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001500:BCG Vaccine / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage*; D003606:Dacarbazine / Q000008:administration & dosage*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000401:mortality / Q000628:therapy*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D014750:Vincristine / Q000008:administration & dosage*
D001500:BCG Vaccine; D014750:Vincristine; D003606:Dacarbazine; D003520:Cyclophosphamide